Should patient enrollment criteria for anti-VEGF phase III trials be reconsidered
J Diabetes
.
2023 Oct;15(10):911-912.
doi: 10.1111/1753-0407.13468.
Epub 2023 Sep 20.
Authors
Joel Hanhart
1
2
,
Sohee Jeon
3
,
Raimo Tuuminen
4
5
6
Affiliations
1
Department of Ophthalmology, Shaare Zedek Medical Center, Jerusalem, Israel.
2
Hebrew University of Jerusalem, Jerusalem, Israel.
3
Vitreoretinal Service, Keye Eye Center, Seoul, South Korea.
4
Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland.
5
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
6
Helsinki Retina Research Group, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
PMID:
37731062
PMCID:
PMC10590675
DOI:
10.1111/1753-0407.13468
No abstract available
Publication types
Clinical Trial, Phase III
Letter
MeSH terms
Humans
Patient Selection
Vascular Endothelial Growth Factor A*
Substances
Vascular Endothelial Growth Factor A